Intensity-modulated X-ray (IMXT) Versus Proton (IMPT) Therapy for Theragnostic Hypoxia-based Dose Painting

Overview

Journal Phys Med Biol

Publisher IOP Publishing

Specialties Biophysics
Nuclear Medicine
Radiology

Date 2008 Jul 19

PMID 18635895

Citations 31

Authors

Ryan T Flynn

Stephen R Bowen

Soren M Bentzen

T Rockwell Mackie

Robert Jeraj

Affiliations

Soon will be listed here.

Abstract

In this work the abilities of intensity-modulated x-ray therapy (IMXT) and intensity-modulated proton therapy (IMPT) to deliver boosts based on theragnostic imaging were assessed. Theragnostic imaging is the use of functional or molecular imaging data for prescribing radiation dose distributions. Distal gradient tracking, an IMPT method designed for the delivery of non-uniform dose distributions, was assessed. Dose prescriptions for a hypoxic region in a head and neck squamous cell carcinoma patient were designed to either uniformly boost the region or redistribute the dose based on positron emission tomography (PET) images of the (61)Cu(II)-diacetyl-bis(N(4)-methylthiosemicarbazone) ((61)Cu-ATSM) hypoxia surrogate. Treatment plans for the prescriptions were created for four different delivery methods: IMXT delivered with step-and-shoot and with helical tomotherapy, and IMPT delivered with spot scanning and distal gradient tracking. IMXT and IMPT delivered comparable dose distributions within the boost region for both uniform and redistributed theragnostic boosts. Normal tissue integral dose was lower by a factor of up to 3 for IMPT relative to the IMXT. For all delivery methods, the mean dose to the nearby organs at risk changed by less than 2 Gy for redistributed versus uniform boosts. The distal gradient tracking method resulted in comparable plans to the spot scanning method while reducing the number of proton beam spots by a factor of over 3.

Citing Articles

Treatment Planning Methods for Dose Painting by Numbers Treatment in Gamma Knife Radiosurgery.

Tham B, Aleman D, Nordstrom H, Nygren N, Coolens C Adv Radiat Oncol. 2024; 9(8):101534.

PMID: 39104874 PMC: 11298584. DOI: 10.1016/j.adro.2024.101534.

Tumour response to hypoxia: understanding the hypoxic tumour microenvironment to improve treatment outcome in solid tumours.

Bigos K, Quiles C, Lunj S, Smith D, Krause M, Troost E Front Oncol. 2024; 14:1331355.

PMID: 38352889 PMC: 10861654. DOI: 10.3389/fonc.2024.1331355.

Voxel-level biological optimisation of prostate IMRT using patient-specific tumour location and clonogen density derived from mpMRI.

Her E, Haworth A, Reynolds H, Sun Y, Kennedy A, Panettieri V Radiat Oncol. 2020; 15(1):172.

PMID: 32660504 PMC: 7805066. DOI: 10.1186/s13014-020-01568-6.

Improving Head and Neck Cancer Treatments Using Dynamic Collimation in Spot Scanning Proton Therapy.

Moignier A, Gelover E, Wang D, Smith B, Flynn R, Kirk M Int J Part Ther. 2019; 2(4):544-554.

PMID: 31772966 PMC: 6871640. DOI: 10.14338/IJPT-15-00026.1.

Trimmer sequencing time minimization during dynamically collimated proton therapy using a colony of cooperating agents.

Smith B, Hyer D, Flynn R, Hill P, Culberson W Phys Med Biol. 2019; 64(20):205025.

PMID: 31484170 PMC: 6995666. DOI: 10.1088/1361-6560/ab416d.

References

Bortfeld T, Jokivarsi K, Goitein M, Kung J, Jiang S . Effects of intra-fraction motion on IMRT dose delivery: statistical analysis and simulation. Phys Med Biol. 2002; 47(13):2203-20. DOI: 10.1088/0031-9155/47/13/302. View

Bentzen S . Theragnostic imaging for radiation oncology: dose-painting by numbers. Lancet Oncol. 2005; 6(2):112-7. DOI: 10.1016/S1470-2045(05)01737-7. View

GRAY L, CONGER A, Ebert M, HORNSEY S, Scott O . The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy. Br J Radiol. 1953; 26(312):638-48. DOI: 10.1259/0007-1285-26-312-638. View

Flynn R, Barbee D, Mackie T, Jeraj R . Comparison of intensity modulated x-ray therapy and intensity modulated proton therapy for selective subvolume boosting: a phantom study. Phys Med Biol. 2007; 52(20):6073-91. PMC: 2712448. DOI: 10.1088/0031-9155/52/20/001. View

Sovik A, Malinen E, Bruland O, Bentzen S, Olsen D . Optimization of tumour control probability in hypoxic tumours by radiation dose redistribution: a modelling study. Phys Med Biol. 2007; 52(2):499-513. DOI: 10.1088/0031-9155/52/2/013. View

Thorwarth D, Eschmann S, Paulsen F, Alber M . A model of reoxygenation dynamics of head-and-neck tumors based on serial 18F-fluoromisonidazole positron emission tomography investigations. Int J Radiat Oncol Biol Phys. 2007; 68(2):515-21. DOI: 10.1016/j.ijrobp.2006.12.037. View

Malinen E, Sovik A, Hristov D, Bruland O, Olsen D . Adapting radiotherapy to hypoxic tumours. Phys Med Biol. 2006; 51(19):4903-21. DOI: 10.1088/0031-9155/51/19/012. View

Eisbruch A, Ten Haken R, Kim H, Marsh L, Ship J . Dose, volume, and function relationships in parotid salivary glands following conformal and intensity-modulated irradiation of head and neck cancer. Int J Radiat Oncol Biol Phys. 1999; 45(3):577-87. DOI: 10.1016/s0360-3016(99)00247-3. View

ODonoghue J, Zanzonico P, Pugachev A, Wen B, Smith-Jones P, Cai S . Assessment of regional tumor hypoxia using 18F-fluoromisonidazole and 64Cu(II)-diacetyl-bis(N4-methylthiosemicarbazone) positron emission tomography: Comparative study featuring microPET imaging, Po2 probe measurement, autoradiography, and.... Int J Radiat Oncol Biol Phys. 2005; 61(5):1493-502. DOI: 10.1016/j.ijrobp.2004.12.057. View

10.

Bortfeld T, Kahler D, Waldron T, Boyer A . X-ray field compensation with multileaf collimators. Int J Radiat Oncol Biol Phys. 1994; 28(3):723-30. DOI: 10.1016/0360-3016(94)90200-3. View

11.

Maurer R, Blower P, Dilworth J, Reynolds C, Zheng Y, Mullen G . Studies on the mechanism of hypoxic selectivity in copper bis(thiosemicarbazone) radiopharmaceuticals. J Med Chem. 2002; 45(7):1420-31. DOI: 10.1021/jm0104217. View

12.

Thorwarth D, Eschmann S, Paulsen F, Alber M . A kinetic model for dynamic [18F]-Fmiso PET data to analyse tumour hypoxia. Phys Med Biol. 2005; 50(10):2209-24. DOI: 10.1088/0031-9155/50/10/002. View

13.

Pedroni E, Bacher R, Blattmann H, Bohringer T, Coray A, Lomax A . The 200-MeV proton therapy project at the Paul Scherrer Institute: conceptual design and practical realization. Med Phys. 1995; 22(1):37-53. DOI: 10.1118/1.597522. View

14.

Eschmann S, Paulsen F, Reimold M, Dittmann H, Welz S, Reischl G . Prognostic impact of hypoxia imaging with 18F-misonidazole PET in non-small cell lung cancer and head and neck cancer before radiotherapy. J Nucl Med. 2005; 46(2):253-60. View

15.

Sovik A, Malinen E, Skogmo H, Bentzen S, Bruland O, Olsen D . Radiotherapy adapted to spatial and temporal variability in tumor hypoxia. Int J Radiat Oncol Biol Phys. 2007; 68(5):1496-504. DOI: 10.1016/j.ijrobp.2007.04.027. View

16.

Dehdashti F, Mintun M, Lewis J, Bradley J, Govindan R, Laforest R . In vivo assessment of tumor hypoxia in lung cancer with 60Cu-ATSM. Eur J Nucl Med Mol Imaging. 2003; 30(6):844-50. DOI: 10.1007/s00259-003-1130-4. View

17.

Dehdashti F, Grigsby P, Lewis J, Laforest R, Siegel B, Welch M . Assessing tumor hypoxia in cervical cancer by PET with 60Cu-labeled diacetyl-bis(N4-methylthiosemicarbazone). J Nucl Med. 2008; 49(2):201-5. DOI: 10.2967/jnumed.107.048520. View

18.

Shepard D, Olivera G, Reckwerdt P, Mackie T . Iterative approaches to dose optimization in tomotherapy. Phys Med Biol. 2000; 45(1):69-90. DOI: 10.1088/0031-9155/45/1/306. View

19.

Levin-Plotnik D, Hamilton R . Optimization of tumour control probability for heterogeneous tumours in fractionated radiotherapy treatment protocols. Phys Med Biol. 2004; 49(3):407-24. DOI: 10.1088/0031-9155/49/3/005. View

20.

Madani I, Duthoy W, Derie C, De Gersem W, Boterberg T, Saerens M . Positron emission tomography-guided, focal-dose escalation using intensity-modulated radiotherapy for head and neck cancer. Int J Radiat Oncol Biol Phys. 2007; 68(1):126-35. DOI: 10.1016/j.ijrobp.2006.12.070. View